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Supplementary Methods
CK2 inhibitors CX-4945 and MB002
CX-4945 (silmitasertib) was purchased from Hölzel Diagnostica GmbH (Cologne, Germany). MB002 was synthesized as described previously 2 .
CK2 inhibitors AR18 and THN27
Overview of AR18 synthesis N-diethylaminoethyltetrahydroindeno [1,2-b] indole (AR18) was synthesized as compound 4 according to a previously reported method 3, 4 outlined in Scheme S1. 
Protein expression and purification
The mutageneses of the CK2 catalytic subunits -Cys336Ser in human CK2α' and the C-terminal truncation in human CK2α -were published previously 6, 7 . CK2α for the co-crystallization with THN27 under high-salt conditions (structure 1 in -S8 -Supplementary Table 1 ) was expressed and purified without a particular affinity tag as described by Raaf et al. 8 In order to prepare CK2α 1-335 for other applications of this study as well as For purification by metal-chelate affinity chromatography, the supernatants of the centrifugations were applied to a HisTrap TM -FF column (GE Healthcare). A solution composed of 20 mM imidazole, 500 mM NaCl, 50 mM Tris/HCl, pH 8.5, was used to equilibrate the column and to wash extensively after application of the protein solutions. In each case, the target protein (CK2α' C336S or CK2α 1-335 ) was eluted with 250 mM imidazole, 500 mM NaCl, 50 mM Tris/HCl, pH 8.5, concentrated via ultrafiltration and further purified by size exclusion chromatography with a HiLoad 16/600 Superdex 200 column (GE Healthcare). The equilibration and running buffer for the gel filtration column was 500 mM NaCl, 25 mM Tris/HCl, pH 8.5. Finally, the proteins were concentrated and re-buffered in 500 mM NaCl, 25 mM Tris/HCl, pH 8.5, by ultrafiltration (AMICON Ultra tubes).
-S9 -The CK2α'2/β2 and the CK2α2/β2 holoenzyme were prepared in order to utilize them in the THN27 inhibition assay (Figure 1h ). To this end, CK2β , a C-terminally truncated variant of human CK2β which is fully competent to interact both with CK2α 9, 10 and with CK2α' 6 , was used. The three proteins were overexpressed separately: CK2α' C336S in E. coli BL21 Gen-X™ (DE3) cells and CK2α 1-335 as well as CK2β in E. coli BL21 Star (DE3) cells. CK2β -containing cells were mixed with either CK2α' C336S -or CK2α 1-335 -containing bacteria and suspended in lysis buffer (500 mM NaCl, 20 mM imidazole, 1 mg/mL hen egg white lysozyme, 10 µg/mL DNase I, 50 mM Tris/HCl, pH 8.5). Subsequently, a preparation procedure was applied which is equivalent to the strategy described above for the individual catalytic subunits CK2α' C336S and CK2α .
Protein kinase assay
The kinase reactions were analyzed with a non-radioactive method based on capillary electrophoresis (CE) 11 in which an established CK2 substrate peptide (sequence RRRDDDSDDD) was phosphorylated and the phosphorylated peptidic The statistical significance of the IC50 differences between either CK2α' C336S and CK2α or the corresponding CK2 holoenzyme complexes were evaluated with -S11 -an unpaired T-test using the GraphPad Prism (GraphPad, La Jolla, USA) as well. For CK2α' C336S and CK2α 1-335 the values were significantly different with a P value < 0.0001 considering a confidence interval of 95 %. Under the identical confidence interval of 95 %, the values obtained for both holoenzymes appeared to be not significantly different.
Crystallization
All crystallization experiments were performed at 20 °C using the sitting drop variant of the vapor diffusion technique with Cryschem 24-well crystallization plates (Hampton Reseach).
CK2α' C336S was co-crystallized with the inhibitor MB002 (Figure 1e ) either for direct diffraction experiments or for subsequent ligand exchange (Figure 3a) . Stock solutions of the enzyme (6 mg/mL CK2α 1-335 in 500 mM NaCl, 25 mM Tris/HCl, pH 8.5) and of the inhibitor (10 mM in DMSO) were prepared and mixed in a 1:9 volume ratio. The resulting mixture was gently stirred and preincubated for 30 min at ambient temperature, followed by subsequent centrifugation at 16100 × g for 10 min. For crystallization 20 µL of this CK2α' C336S /MB002 solution was supplemented with 10 µL vapor diffusion reservoir solution with an initial composition of 28 % (v/v) PEG 6000, 500 mM LiCl, 100 mM Tris/HCl, pH 8.5. The reservoir solution was subject to intensive optimization (Figure 3a ) in order to generate CK2α' C336S /MB002 crystals suitable for subsequent macro-seeding and finally inhibitor exchange. The most effective change was to raise the LiCl concentration to finally 900 mM. Thus, the optimal reservoir solution that was used to grow the CK2α' C336S /MB002 crystals for structures 3-5 in Supplementary Table 1 was 28 % (w/v) PEG 6000, 900 mM LiCl, 100 mM Tris/HCl, pH 8.5. In the case of the CK2α' C336S /AR18 complex (structure 6 in Supplementary Table 1) the LiCl concentration of the reservoir solution was 700 mM.
-S12 -Furthermore, seeding methods were required to achieve large and compact CK2α' C336S /MB002 crystals. Two cycles of micro seeding with selection of optically defect-free crystals were performed. They were followed by macro seeding experiments in which in each case a single macro seed was transferred into a pre-equilibrated droplet of the same composition as the original mother liquor. These crystals were grown until the desired edge size was achieved.
In the case of the CK2α 1-335 /THN27 structures stock solutions of the enzyme (6 mg/mL CK2α 1-335 in 500 mM NaCl, 25 mM Tris/HCl, pH 8. 
Dehydration, inhibitor exchange and cryo protection
CK2α' C336S /MB002 crystals were detached from the ground of the crystal plates and transferred into droplets lacking MB002 and CK2α' C336S , but containing the same salt and PEG concentration as the mother liquor. This purging step was carried out to remove unbound MB002. Next, the PEG 6000 concentration was raised to the solubility limit over a period of 1 week in order to stabilize the crystal by dehydration. 
X-ray diffraction data collection and processing
X-ray diffraction data were obtained at the European Synchrotron Radiation Facility (ESRF) in Grenoble (France) and at the EMBL outstation at DESY (Deutsches Elektronensynchrotron) in Hamburg (Germany). The corresponding beamlines are mentioned in Supplementary Table 1. All datasets were collected under constant nitrogen flow (100 K). The diffraction data were indexed and integrated using XDS 12 followed by scaling with XSCALE from the XDS package 12 . The high-resolution limit was estimated from the statistics in the XSCALE logfile and set in such a way that in the highest-resolution shell the signal-to-noise ratio (I/σI) is above 1 and that simultaneously the CC1/2-value is larger than 0.5.
Structure solution and refinement
The four CK2α' C336S structures were phased ab initio using ARCIMBOLDO_LITE 13 implemented in the CCP4 package 14 . Subsequently, automated model building was performed with ARP/wARP 15 . The two CK2α 1-335 /THN27 structures were determined -S14 -with molecular replacement using PHASER 16 and either the PDB file 5ONI 17 (low-salt CK2α 1-335 /THN27 complex) or the PDB file 5CQU 18 (high-salt CK2α 1-335 /THN27 complex) as search model. The inhibitor molecules were parameterized with eLBOW 19 and fitted into the electron densities with COOT 20 which was further used for manual model building and validation. Computational refinement was performed with PHENIX 1 .
Illustrations and photographs
The structural formula in Chart 1 were drawn with MARVIN JS (ChemAxon Ltd.). The structure illustrations in Figure 3 and Figure 4 were prepared with PYMOL (Schrödinger, LLC.) 21 . The outline of the crystallization procedure in Figure 3a was produced with Inkscape (www.inkscape.org) 22 . For each of the crystal pictures in Figure 3a we used CombineZP (www.hadleyweb.pwp.blueyonder.co.uk) to calculate a Z-stag of two-dimensional crystal photos. The two-dimensional interaction projection in the Graphical Abstract was drawn with LIGPLOT 23 .
